Mast cells in meningiomas

Submitted: 19 January 2024
Accepted: 19 March 2024
Published: 18 April 2024
Abstract Views: 73
PDF: 81
HTML: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Meningioma represents the most frequent tumor of the central nervous system (CNS). Correlations between the presence of mast cells (MCs) and grade or other histological features of meningioma are still debated. Our study aimed to better understand the relationship between mast cells and meningiomas and to compare our results based on specific histological subtypes and novel 2021 CNS WHO grading system. We observed some differences as regards the number of MCs and meningioma grade. In low-grade (grade 1) meningiomas, MCs were observed in 7/22 cases, while they were consistently present in all eight high-grade cases (grade 2 and grade  3). Among the grade 1 meningiomas, we observed two “low-positive”, two “intermediate-positive”, and three “high-positive” cases. Among the group of high-grade meningiomas, the six cases grade 2 were considered as “low-positive”, while the two grade 3 cases showed a higher number of MCs and were included in the “intermediate-positive” group. Even though with no statistical significance, due to the low number of cases, our results seem to confirm a sort of relationship between meningioma grading and the number of MCs, as demonstrated by the higher percentage of high-grade meningiomas showing MCs infiltrates, compared to low-grade meningiomas.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol 2022;24:v1-v95. DOI: https://doi.org/10.1093/neuonc/noac202
Kemnitz, P, Spormann H, Heinrich P. Meningioma of lung: first report with light and electron microscopic findings. Ultrastruct Pathol 1982;3:359-65. DOI: https://doi.org/10.3109/01913128209018558
Kershisnik M, Callender DL, Batsakis JG. Extracranial, extraspinal meningiomas of the head and neck. Ann Otol Rhinol Laryngol 1993;102:967-70. DOI: https://doi.org/10.1177/000348949310201211
Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004;70:183-202. DOI: https://doi.org/10.1007/s11060-004-2749-0
World Health Organization. Female Genital Tumours. WHO Classification of Tumours Series. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231-51. DOI: https://doi.org/10.1093/neuonc/noab106
Hasselblatt M, Nolte KW, Paulus W. Angiomatous meningioma: A clinicopathologic study of 38 cases. Am J Surg Pathol 2004;28:390. DOI: https://doi.org/10.1097/00000478-200403000-00013
Bitzer M, Nägele T, Geist-Barth B, Klose U, Grönewäller E, Morgalla M, et al. Role of hydrodynamic processes in the pathogenesis of peritumoral brain edema in meningiomas. J Neurosurg 2000;93:594-604. DOI: https://doi.org/10.3171/jns.2000.93.4.0594
Bujan B, Mennel HD. Elevated numbers of mast cells in angiomatous meningioma. Clin Neuropathol 2015;34:54-6. DOI: https://doi.org/10.5414/NP300779
Tirakotai W, Mennel HD, Celik I, Hellwig D, Bertalanffy H, Riegel, T. Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration. Neurosurg Rev 2006;29:41-8. DOI: https://doi.org/10.1007/s10143-005-0402-9
Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharide T.C. Mast cells in meningiomas and brain inflammation. J Neuroinflammation 2015;12:170. DOI: https://doi.org/10.1186/s12974-015-0388-3
Reszec J, Hermanowicz A, Kochanowicz J, Turek G, Mariak Z, Chyczewski L. Mast cells evaluation in meningioma of various grades. Folia Histochem Cytobiol 2012;50:542-6. DOI: https://doi.org/10.5603/14744
Reszec J, Hermanowicz A, Rutkowski R, Bernaczyk P, Mariak Z, Chyczewski L. Evaluation of Mast cells and hypoxia inducible factor-1 expression in meningiomas of various grades in correlation with peritumoral brain edema. J Neurooncol 2013;115:119-25. DOI: https://doi.org/10.1007/s11060-013-1208-1
Bø L, Mørk SJ, Nyland H. An immunohistochemical study of mononuclear cells in meningiomas. Neuropathol Appl Neurobiol 1992;18:548-58. DOI: https://doi.org/10.1111/j.1365-2990.1992.tb00825.x
Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta 2012;1822:2-8. DOI: https://doi.org/10.1016/j.bbadis.2010.11.010
Zhao J, Hou Y, Yin C, Hu J, Gao T, Huang X, et al. Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma. Oncogene 2020;39:1724-38. DOI: https://doi.org/10.1038/s41388-019-1093-y
Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, et al. Pathodiagnostic parameters for meningioma grading. J Clin Neurosci 2008;15:1370-5. DOI: https://doi.org/10.1016/j.jocn.2007.12.005
Haslund-Vinding J, Møller JR, Ziebell M, Vilhardt F, Mathiesen T. The role of systemic inflammatory cells in meningiomas. Neurosurg Rev 2022;45:1205-15. DOI: https://doi.org/10.1007/s10143-021-01642-x

Ethics Approval

this study was approved by the Institutional Review Board at the Bari Policlinico Hospital, University of Bari “Aldo Moro”

Supporting Agencies

European Union Seventh Framework Program

How to Cite

D’Amati, A., Tamma, R., Annese, T., Rizzi, A., & Ribatti, D. (2024). Mast cells in meningiomas. European Journal of Histochemistry, 68(2). https://doi.org/10.4081/ejh.2024.3973